GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
Status:
Completed
Trial end date:
2007-12-10
Target enrollment:
Participant gender:
Summary
This is two-part study (Phase I/Phase II). Part I is designed to find the optimal (best)
doses of GW572016 and trastuzumab when given together,Part II is designed to evaluate the
tumor response rate (shrinkage or lack of growth) in patients receiving lapatinib and
trastuzumab.